Tiffany A. Traina, MD, FASCO; Melissa Rikal, MSN, FNP-BC, AOCNP, and Marissa Marti-Smith, DNP, APRN, AGNP-C, AOCNP discuss how emerging treatment strategies and molecular profiling are transforming the management of metastatic hormone receptor-positive, HER2-negative breast cancer, with a specific focus on ESR one mutations and the potential of new targeted therapies like L-acstrin.
EP. 1: When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case
Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in patients with metastatic breast cancer, particularly as a mechanism of resistance to aromatase inhibitor treatment.
EP. 5: From Trial to Practice: Real-World Outcomes and The Evolving SERD Landscape
June 5th 2025Panelists discuss how real-world data from the San Antonio Breast Cancer Symposium demonstrated that elacestrant's performance in actual clinical practice even exceeded the promising results from the clinical trial.